Biotechnology company, SCYNEXIS, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral ibrexafungerp for the treatment of vulvovaginal...

SCYNEXIS, Inc. announced this week positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment...

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global...

Around 138 million women are affected by a distressing but treatable fungal infection world-wide, according to a research review by University of Manchester scientists. And the incidence of recurrent...

New Jersey based biotechnology company, SCYNEXIS, Inc. announced this week that the U.S. Food and Drug Administration(FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track...